Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06368609
Other study ID # 2024-09
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 2024
Est. completion date May 2024

Study information

Verified date April 2024
Source IRCCS Sacro Cuore Don Calabria di Negrar
Contact Elvia Malo
Phone +390456014854
Email ricerca.clinica@sacrocuore.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Single center, no profit experimental study on sera available in the Tropica Biobank.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date May 2024
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Serum from immigrants from S. stercoralis endemic countries (i.e. individuals from Africa, Latin America, South-East Asia and western Pacific regions); - Serum with a matched result of APC and/or PCR for S. stercoralis (i.e. the latter test/s done in the same day or ±30 days from the collection of the serum) and of serology assays (IFAT and/or ELISA) in use in our laboratory. Exclusion Criteria: - Unavailable/insufficient quantity of serum - Serum from individuals who received treatment with ivermectin in the previous 6 months.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
IgG RDT
Sera will be thawed at room temperature; 15 µL of serum will be added to the sample pad of each dipstick, which will then be placed upright into a well containing 3 drops of buffer. The pads at the bottom of the dipstick shall then wick up the buffer to run up the nitrocellulose membrane towards the absorbent pad. The results can be read after 15-20 minutes. The presence of the control line will indicate proper execution of the test, with valid result. In case of absence of this line, the result will be considered invalid. Positive results will be defined as test with presence of both control and positive (including faint) lines; negative results will be defined as tests with presence of control line only.
IgG4 RDT
Sera will be thawed at room temperature; 15 µL of serum will be added to the sample pad of each dipstick, which will then be placed upright into a well containing 3 drops of buffer. The pads at the bottom of the dipstick shall then wick up the buffer to run up the nitrocellulose membrane towards the absorbent pad. The results can be read after 15-20 minutes. The presence of the control line will indicate proper execution of the test, with valid result. In case of absence of this line, the result will be considered invalid. Positive results will be defined as test with presence of both control and positive (including faint) lines; negative results will be defined as tests with presence of control line only.

Locations

Country Name City State
Italy IRCCS Sacro Cuore Don Calabria hospital Negrar Verona

Sponsors (1)

Lead Sponsor Collaborator
IRCCS Sacro Cuore Don Calabria di Negrar

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary RDTs IgG results: positive or negative RDTs (IgG) results will be classified as positive or negative according to the manufacturer instructions. For the composite reference standard definition: a true positive will be defined as at least one positive faecal test result. True negative will be defined as all test results (faecal and serological) being negative. baseline
Primary RDTs IgG4 results: positive or negative RDTs (IgG4) results will be classified as positive or negative according to the manufacturer instructions. For the composite reference standard definition: a true positive will be defined as at least one positive faecal test result. True negative will be defined as all test results (faecal and serological) being negative. baseline
Secondary Agreement between readers Agreement between two independent readers of the RDTs results baseline
See also
  Status Clinical Trial Phase
Completed NCT04999774 - Evaluation of Strongyloidiasis in Ecuador: a fieLd Laboratory Accuracy Study
Enrolling by invitation NCT04056325 - Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis Phase 2
Terminated NCT03605758 - Treatment of Strongyloides Infection Phase 3
Not yet recruiting NCT06373835 - Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis Phase 2
Completed NCT06308705 - The SsRI/NIE Recombinant Antigen ELISA for the Follow up of Patients Infected by Strongyloides Stercoralis N/A
Completed NCT04848688 - Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis Phase 3
Recruiting NCT01308268 - Management of Soil-transmitted Helminthiasis and Strongyloidiasis N/A